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Abstract 
Purpose The primary aim of this study was to evaluate the influence of aminobisphosphonates on the 
osteogenesis of hBMSCs and mineralization of differentiating bone-forming cells isolated from 
osteoporotic patients. 
Methods The influence of aminobisphosphonate treatment on hBMSC osteogenesis was assessed by the 
quantitative measurement of alkaline phosphatase (ALP) activity, in addition to qRT-PCR and Western 
blot analysis of known osteogenic markers. Mineralized matrix formation by hBMSC-derived osteoblasts 
was visualized and quantified using Alizarin red staining.  
Results hBMSC cultures treated with osteogenic medium supplemented with zoledronate demonstrated a 
significant increase in Alizarin red staining after 3 weeks as compared to cells cultured in osteogenic 
medium alone. Similarly, cultures of differentiating hBMSCs isolated from patients receiving alendronate 
treatment also demonstrated an increased propensity for mineralization, even in the absence of further in 
vitro stimulation by zoledronate. The stimulatory effects of aminobisphosphonate treatment on hBMSC-
derived osteoblast formation were independent of any alterations in ALP activity, although significant 
changes in the expression levels of osteopontin (SPP1) were evident in hBMSCs following exposure to 
aminobisphosphonates. Further analysis revealed osteopontin as having a negative influence on the 
mineralization of differentiating osteoporotic bone-forming cells. 
Conclusions The results presented here demonstrate for the first time that aminobisphosphonate treatment 
of osteoporotic hBMSCs enhances their capacity for osteoblast formation and subsequent mineral 
deposition, thus supporting the concept of aminobisphosphonates as having an osteoanabolic effect in 
osteoporosis.  
 
Keywords: Osteoporosis; Aminobisphosphonate; Bone marrow stromal cell; Osteogenic differentiation; 
mineralization. 
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Mini Abstract 
In the present study, we evaluated the potential for aminobisphosphonates to enhance the development of 
bone-forming osteoblasts from progenitor cells isolated from aged female osteoporotic patients. The 
aminobisphosphonates tested significantly enhanced osteoblast formation and thus lend further insights 
into their possible mode of action in the treatment of osteoporosis. 
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Introduction 
Age-related bone loss results from an imbalance between bone resorption and bone formation due to a 
spatially or temporally uncoupled activity of bone resorbing osteoclasts and bone forming osteoblasts
 
[1]. 
The latter are derived from progenitor cells within the bone marrow termed bone marrow stromal cells 
(BMSCs), through a process of osteogenic differentiation. The ability to produce a sufficient number of 
functionally active osteoblasts is pivotal to preserving bone mass and represents an essential step in the 
continuous, complex and well orchestrated process of bone remodeling [2]. There is now a growing body 
of evidence to suggest that BMSCs are critically involved in the pathogenesis of osteoporosis [3-9], thus 
implying that the structural abnormalities associated with osteoporotic bone maybe as a consequence of 
inadequacies in bone cell differentiation. This concept is further supported by findings from studies 
investigating the role of BMSCs in experimental models of osteoporosis and ageing. Results from our 
own studies, as well as research performed by others, have shown that the osteoporotic-like phenotype 
observed in senescence-accelerated mouse prone 6 strain (SAMP6) mice is associated with deficits in the 
osteogenic differentiation potential of resident BMSCs [10-11]. Similarly, impaired BMSC osteogenesis 
has been observed in several transgenic mouse models in which many of the characteristic features of 
senile osteoporosis are evident [12-15]. Clearly therefore, stimulation of resident BMSC populations to 
undergo osteogenic differentiation through therapeutic intervention may be key to the success of treating 
osteoporosis in aged individuals. 
The majority of current treatments available for osteoporosis are directed towards preventing bone 
resorption, with bisphosphonate therapy being the most widely used anti-resorptive approach to enhance 
bone strength in osteoporotic patients [16]. Bisphosphonates are a well-characterized class of synthetic 
compounds structurally related to pyrophosphate, and are thought to mediate their antiresorptive actions 
primarily through inhibition of osteoclast activity [17]. However, there are now an increasing number of 
reports alluding to the idea that the preventative effects of bisphosphonates on bone loss, maybe 
additionally mediated through their anabolic effects on cells of the osteoblastic lineage. In the majority of 
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cases, both amino- and non-aminobisphosphonates have been found to enhance osteogenic differentiation 
of human BMSCs (hBMSCs) [18-21]. These observations have also been extended to human adipose-
derived stromal cells (hASCs), where alendronate treatment not only stimulated osteogenesis in vitro, but 
also enhanced bone repair in a rat critical-sized calvarial defect model when delivered locally on a 
hASC/PLGA scaffold construct [22]. However, despite these observations, no study has yet examined the 
effects of bisphosphonates on hBMSCs isolated from osteoporotic patients, even though they are the 
primary target group for bisphosphonate treatment. The need for such investigations is further highlighted 
by the fact that hBMSCs from osteoporotic patients are considered to be molecularly distinct from their 
non-osteoporotic counterparts and may therefore not respond in the same way to bisphosphonate 
treatment [23]. 
In the present study, we aim to address this issue by evaluating the potential of aminobisphosphonates to 
enhance osteogenic differentiation of hBMSCs isolated from aged female osteoporotic patients. In vitro 
cultures of hBMSCs were incubated with zoledronate and their ability to differentiate towards osteoblasts 
assessed through the use of molecular, biochemical and histological techniques. Furthermore, the 
osteogenic differentiation potential of hBMSCs isolated from osteoporotic patients undergoing 
alendronate therapy was also evaluated. We hypothesized that exposure of osteoporotic hBMSCs to 
aminobisphosphonate would significantly increase their capacity for osteoblastogenesis and subsequent 
mineralization. 
 
Materials and methods 
Patients  
BMSCs were isolated from a total of 10 aged female osteoporotic donors undergoing routine surgical 
procedures for proximal femur fracture at the Department of Trauma Surgery, University Hospital 
Innsbruck, Austria (Table 1). All procedures were carried out in accordance with the ethics commission 
guidelines for Innsbruck Medical University. Inclusion criteria consisted of patients being > 65 years of 
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age and having sustained a proximal femoral fracture after a low-energy trauma. Osteoporosis was 
confirmed in these patients using dual energy X-ray absorptiometry (DXA; Hologic QDR 4500) where 
those patients showing a bone mineral density T-score of -2.5 standard deviations (SD) or less at the 
contralateral hip and/or lumbar spine were considered osteoporotic. In three of the cases, patients had 
been receiving aminobisphosphonate treatment for > 3 years.  
 
Cell culture 
Bone marrow was harvested from the femoral medullary cavity of patients undergoing routine surgery 
and hBMSCs isolated according to a well established protocol [24]. Purified hBMSCs were maintained at 
37 °C, in 5% CO2 and 98% humidity in normal growth medium consisting of Dulbecco’s modified eagle 
medium (DMEM-low glucose, with L-Glutamine) (PAA Laboratories GmbH, Pasching, Austria), 
supplemented with 10% fetal bovine serum (FBS) (Biowest, Nuaillé, France) and 1% penicillin 
(50 units/ml) and streptomycin (50 µg/ml) (PAA Laboratories GmbH, Pasching, Austria). The medium 
was changed twice a week. Cells were used at passage 4 unless otherwise stated. For all experiments 
hBMSCs were cultured in 96-, 48- and 6-well culture plates (Sarstedt, Wiener Neudorf, Austria), seeded 
at densities of 4 x10
3
 and 5 x10
4 
cells per well respectively. After 72 h, cells were washed and used for 
experimental analysis. 
 
Fluorescence activated cell sorting (FACS) analysis of surface markers 
hBMSCs were directly stained with phycoerythrin labeled antibodies (Biozym Scientific GmbH, 
Oldendorf, Germany) specific for CD90, CD105, CD166, CD34 and CD45. Specificity was confirmed 
through the use of appropriate phycoerythrin-labeled isotype control antibodies and viability assessed 
using 7-AAD (1 µg/ml) (Sigma, Vienna, Austria). Flow cytometry was carried out on a FACScan (BD 
Biosciences, Schwechat, Austria) and staining analyzed using WinMDI2.8 freeware. 
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hBMSC differentiation 
hBMSCs were induced to undergo either adipogenesis or osteogenesis using well-recognized 
differentiation protocols previously established in our laboratory [25]. Adipocyte formation was 
confirmed by positive staining of triglyceride using Oil red O (Sigma-Aldrich, Vienna, Austria). In order 
to investigate the effects of aminobisphosphonate treatment on hBMSC osteogenesis, osteogenic 
induction medium (OM) consisting of normal growth medium supplemented with 50µM L-Ascorbic acid 
2-phosphate (Sigma-Aldrich), 10mM β-glycerophosphate (Sigma-Aldrich) and 100nM dexamethasone 
(Sigma-Aldrich), was supplemented with zoledronate (10 and 100 nM) where stated. Mineralization was 
visualized using Alizarin red and the amount of staining quantified in pooled samples from individual 
patients using a spectrophotometer following Alizarin red extraction using cetylpyridinium chloride 
(Sigma-Aldrich, Vienna, Austria). Optical densities were converted to nanomoles (nM) of Alizarin red 
using a standard curve and normalized to cell number. The mean cell number was determined by 
automated counting of Hoechst 33258 stained nuclei in at least 9 random fields of view. Images were 
captured on a Leica DMI 3000 B inverse fluorescence microscope equipped with a DIC 450 C camera 
and LAS V 4.0 software (all Leica, Microsystems, Wetzlar, Germany). Image processing and nucleus 
counts were performed with Cell Profiler cell image analysis software version 2.0 (Scientific Volume 
Imaging, Hilversum, The Netherlands). ALP activity was quantified in cell lysates using p-
nitrophenylphosphate (pNPP) liquid substrate (Sigma-Aldrich, Buchs, Switzerland) and normalized to 
total protein content and reaction time. The expression levels of differentiation markers specific to 
adipogenesis or osteogenesis were measured by quantitative polymerase chain reaction (qRT-PCR) as 
detailed below.  
 
qRT-PCR 
Total RNA was purified from hBMSCs using TRI Reagent (Sigma-Aldrich, Vienna, Austria) and treated 
with TURBO DNase (Life Technologies, Zug, Switzerland). Equal amounts of RNA were combined to 
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form the groups Control (BMSCs from untreated patients; n=5), Control+ZA (BMSCs from untreated 
patients treated with zoledronate in vitro; n=5), ALN (BMSCs from patients treated with alendronate; 
n=3), ALN+ZA (BMSCs from patients treated with alendronate and further treated with zoledronate in 
vitro; n=3). RNA (0.5 µg) was reverse-transcribed using Superscript II (Life Technologies) as described 
previously [25]. An equivalent of 10 or 20 ng total RNA was applied as cDNA template in the successive 
qRT-PCR reactions using the StepOnePlus (Life Technologies). Quantification of mRNA expression was 
performed with TaqMan Gene Expression Assays (Life Technologies) specific for runt-related 
transcription factor 2 (RUNX2) (Hs01047976_m1), osteocalcin (OCN) (Hs01587814_g1), secreted 
phosphoprotein 1/osteopontin (SPP1) (Hs00959010_m1) and fibroblast growth factor (FGF2) 
(Hs00266645_m1), and values normalized to the housekeeping gene, beta glucuronidase (GUSB) 
(Hs99999908_m1). All reactions were performed in fast optical 96-well reaction plates (Life 
Technologies) at 95 
o
C for 20 s, 40 cycles of 95 
o
C for 1 s and 60 
0
C for 20 sec. The mean fold changes 
from three separate experiments were analyzed using the 2
-∆∆CT
 method. 
 
SPP1 small interfering RNA (siRNA) 
Specific knock down of SPP1 expression was performed with Silencer Select siRNA oligos, (Ambion, 
Life Technologies) according to the manufacturer’s protocol. Osteoporotic hBMSCs (1x10
5
 cells) were 
transfected with 100 nM SPP1-specific (S13376) or negative control siRNA (Negative Control-1) using 
the NEON Transfection System (Life Technologies) as previously described [25]. Following transfection, 
cells were seeded in cell culture plates with fresh growth medium (without antibiotics) and incubated for 
24 h at 37°C, 5% CO2. Medium was then replaced with either fresh growth medium or differentiation 
medium and total RNA harvested at day 7 to confirm SPP1 mRNA knockdown. Mineral formation was 
assessed after 28 days using Alizarin red. 
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Western blot analysis of osteopontin 
Protein was extracted using CelLytic M (Sigma-Aldrich) containing a protease inhibitor cocktail (Sigma-
Aldrich) and protein amounts determined by BioRad Protein Assay (BioRad, Reinach, Switzerland). 
Protein samples were boiled for 5 min in loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% 
glycerol, 100 mM DTT, 0.002% Bromophenol blue) and equal amounts of protein loaded onto 4-15% 
Mini-PROTEAN TGX Precast gels (BioRad). Protein was then electroblotted onto PVDF membranes 
using the Trans-Blot Turbo blotting system (BioRad) and incubated in 5% skimmed milk, 50 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20 (TBST) for 1 h at room temperature. Membranes were then 
incubated overnight at 4
o
C with either rabbit anti-human osteopontin (1:1000) (Abcam, UK) or mouse 
anti-human tubulin (1:4000) (Sigma-Aldrich). After washing in TBST three times for 5 min each, 
membranes were incubated with a HRP-conjugated anti-mouse IgG (1:10’000) (Jackson 
ImmunoResearch, UK) for 1 h at room temperature. Following a further washing step, peroxidase activity 
was detected using SuperSignal West Dura Chemiluminescent Substrate (Thermo Scientific, Lausanne, 
Switzerland). 
 
Statistical analysis 
All statistical analyses were carried out using SPSS20.0 (SPSS Inc., Chicago, IL). Parametric analysis of 
data was performed using the two-tailed unpaired Student’s t-test for comparison of two groups or one-
way analysis of variance (ANOVA) followed by Tukey’s post-hoc test for multiple group comparisons. In 
all cases, a p-value of <0.05 was considered statistically significant, and all data were expressed as mean 
± standard deviation (SD). 
 
Results 
Characterization of hBMSCs isolated from osteoporotic patients 
hBMSCs isolated from osteoporotic patients expressed high levels of various markers associated with 
mesenchymal stem cells, including CD90, CD105, and CD166, and low levels of haematopoietic markers 
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CD34 and CD45 (Fig. 1a). Undifferentiated cells displayed typical fibroblast-like appearance (Fig. 1b) 
and multipotency was also demonstrated in these cell populations through their ability to differentiate into 
adipocytes  (Fig. 1c) and osteoblasts (Fig. 1d).  
 
Effect of zoledronate on the mineral formation by differentiating hBMSCs isolated from osteoporotic 
patients 
hBMSCs from osteoporotic patients were further evaluated for their ability to undergo osteogenic 
differentiation and subsequent mineralization following their incubation for up to 21 days in osteogenic 
induction medium (OM) supplemented with or without 10 or 100 nM zoledronate. The degree of mineral 
formation was visualized and quantified by Alizarin red staining. Treatment with zoledronate consistently 
enhanced mineral formation over the 3 week treatment period in a concentration dependent manner (Fig. 
2a and b). Significant increases in Alizarin red staining at 2 weeks post induction were only observed in 
cell cultures exposed to the highest concentration of zoledronate tested (100 nM; p<0.05), although a 
significant effect on mineral formation was observed with both 10 (p<0.01) or 100 nM (p<0.01) 
zoledronate by 3 weeks (Fig. 2a and b). The lower concentration of zoledronate (10 nM) had no 
significant effect on cell numbers during the 3 weeks of treatment as compared to cells treated without 
zoledronate (Fig. 2c). However, cell numbers in cultures treated with the higher concentration of 
zoledronate (100 nM) were significantly reduced at day 14 (p<0.05) and at day 21 (p<0.01) and remained 
at levels comparable to those observed in uninduced cells (Fig. 2c). 
 
Comparison between osteogenic differentiation of hBMSCs isolated from untreated and alendronate-
treated osteoporotic patients  
We next isolated hBMSCs from osteoporotic patients undergoing alendronate therapy (ALN) and directly 
compared their osteogenic potential with hBMSCs from osteoporotic patients without bisphosphonate 
medication (Control). In all cases, hBMSCs isolated from alendronate-treated patients demonstrated a 
greater tendency towards osteoblast formation than patients not receiving alendronate treatment as 
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confirmed by significant increases in Alizarin red staining at days 14 (p<0.01) and 21 (p<0.01)  (Fig. 3a 
and b). In addition, hBMSCs from osteoporotic patients receiving alendronate medication were also 
induced to undergo osteogenesis for up to 21 days in osteogenic medium supplemented with zoledronate 
at 10 (ALN+10 nM ZA) or 100 nM (ALN+100 nM ZA). In contrast to our initial findings using hBMSCs 
isolated from non-bisphosphonate treated osteoporotic patients, zoledronate was only capable of 
enhancing mineralization in cultures of differentiating BMSCs isolated from alendronate-treated patients 
after 3 weeks of treatment, and only when the highest concentration of zoledronate was used (ALN+100 
nM ZA vs. ALN; p<0.01). However, these increases in mineralization due to zoledronate treatment 
(ALN+100 nM) were also associated with significant reductions in cell numbers as compared to control 
cultures at day 14 (p<0.01) and day 21 (p<0.01) (Fig. 3c).  
 
Effect of aminobisphosphonate treatment on ALP activity and osteogenic gene expression in 
differentiating hBMSCs  
In order to ascertain whether the stimulatory effects of aminobisphosphonate treatment on hBMSC 
osteogenic activity were also apparent at the biochemical and molecular level, we analyzed both ALP 
protein activity and the expression levels of several osteogenic markers in cultures of hBMSCs 
undergoing osteogenic differentiation. A 2- to 3-fold increase in ALP enzyme activity was calculated for 
differentiating hBMSCs from each treatment group by day 14 following osteogenic induction (Fig. 4a). 
However, despite our previous observation that exposure to aminobisphosphonate greatly enhances 
hBMSC-derived osteoblast mineralization, we were unable to observe any significant increases in ALP 
enzyme activity in hBMSCs treated with zoledronate (ZA; 100 nM) or in hBMSCs isolated from patients 
treated with alendronate (ALN). The expression levels of RUNX2 did not significantly change during 
osteogenic differentiation in any of the groups tested (Fig. 4b). Expression levels of FGF2 (Fig. 4c) and 
OCN (Fig. 4d) were significantly reduced upon osteogenic induction, and were found to be comparable 
between all treatment groups. In contrast, both zoledronate and alendronate had a marked inhibitory effect 
on SPP1 gene expression (Fig. 4e). Zoledronate induced a significant reduction in SPP1 expression in 
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hBMSCs from untreated patients (Control+ZA) at 7 (0.4-fold ± 0.09; p<0.01) and 14 (0.4-fold ± 0.06; 
p<0.01) days following osteogenic induction. Similarly, SPP1 expression was also significantly reduced 
in hBMSCs from alendronate-treated patients (ALN) at day 7 (0.4-fold ± 0.07; p<0.01) post osteogenic 
induction. Zoledronate treatment of these cells (ALN+ZA) enhanced this effect by inducing a more 
sustained decrease in SPP1 expression for up to 14 days (p<0.05).  
 
Effect of osteopontin on the mineralization efficiency of differentiating bone-forming cells isolated from 
osteoporotic patients. 
Further studies were performed in order to assess the involvement of osteopontin in determining the 
mineralizing capabilities of osteoporotic hBMSC-derived osteoblasts. Western blot analysis revealed 
marked reductions in osteopontin protein levels in differentiating osteoporotic hBMSCs treated with 
either 10 or 100 nM zoledronate for 10 days as compared to control cultures (Fig. 5a). Loss-of-function 
studies in differentiating osteoporotic hBMSCs through the use of a siRNA specific for SPP1 resulted in a 
>140-fold decrease in SPP1 mRNA expression as compared to cells transfected with a siRNA control 
oligonucleotide (Fig. 5b). Subsequently, these cells demonstrated a noticeable increase in mineral 
formation after 28 days of osteogenic induction as compared to cells treated with the siRNA control 
oligonucleotide (Fig. 5c). 
 
Discussion 
Bisphosphonates are considered as one of the first-line therapies for osteoporosis and are the most 
commonly prescribed agents to prevent bone loss and subsequent fractures [26, 27]. Their selective 
adsorption to mineral surfaces and uptake by resident osteoclasts has given rise to the generally accepted 
opinion that bisphosphonates exert their anti-resorptive effects primarily through modification of 
hydroxyapatite crystal dissolution and osteoclast activity [28]. Indeed, numerous studies have confirmed 
that bisphosphonates can directly influence osteoclast resorptive activity through alterations in osteoclast 
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formation and viability [29-32]. Moreover, the cellular and biochemical mechanisms through which these 
effects are brought about have since been elucidated, thus providing us with an even deeper understanding 
of how bisphosphonates may function to prevent bone loss [33]. 
It has been known for some time that bisphosphonates have the potential to prevent apoptosis in bone-
forming osteoblasts and osteocytes in vitro [34, 35], although information relating to their ability to 
directly influence bone formation through stimulation of such cells remains limited [36, 37]. It is 
becoming increasingly evident however, that bisphosphonates may have an indirect effect on bone quality 
through their potential to enhance osteogenesis in differentiating BMSCs. Although thought to represent 
only 0.001 to 0.01% of the total cell population found in bone marrow [38], BMSCs play a crucial role in 
maintaining normal bone homeostasis through their capacity for osteoblastic differentiation [39]. The 
influence of bisphosphonates on BMSC-derived osteoblast formation was originally described by Giuliani 
et al. [18], where cultures of bone marrow cells treated with low doses of either etidronate or alendronate 
resulted in increased numbers of colony forming units for osteoblasts (CF-OBs). Moreover, bone marrow 
cells isolated from bisphosphonate-treated mice also demonstrated an increased potential for CF-OB 
formation, thus suggesting that the stimulatory effects of bisphosphonates on osteoblastogenesis were also 
evident in vivo. Several more reports have since confirmed these initial findings using different 
bisphosphonates and alternative stem cell sources [19-22]. However, up until now, no studies have sought 
to determine the effects of bisphosphonates on hBMSCs isolated from osteoporotic patients and to 
evaluate their potential osteoanabolic influence on these cells. 
In the current report, we successfully isolated and characterized hBMSCs from aged female osteoporotic 
patients. We have confirmed our hypothesis that in vitro treatment of these hBMSC populations with 
zoledronate during osteogenic differentiation could greatly enhance their potential for osteoblastogenesis 
as demonstrated by a significant increase in mineral deposition. Moreover, we could also demonstrate that 
hBMSCs isolated from osteoporotic patients receiving treatment with alendronate were also subject to 
enhanced osteoblastogenesis under normal osteogenic culture conditions. The potential for alendronate to 
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enhance osteoblast formation in vivo may represent an additional mechanism by which bone mineral 
density (BMD) is increased in osteoporotic patients receiving aminobisphosphonate therapy [40]. 
Furthermore, the fact that we were able to visualize enhanced mineral formation in osteoblasts derived 
from these hBMSCs in the absence of further in vitro aminobisphosphonate stimulation, suggests that 
these cells have the potential to retain their enhanced osteogenic capacity, a trait that may also exist in 
vivo during extended periods of bisphosphonate discontinuation. If confirmed, this theory may be of 
clinical importance when considering replacement therapies during time off from bisphosphonate 
treatment [41].  Moreover, such findings may also be of significant relevance when considering the long 
term effects of aminobisphosphonate treatment. Numerous reports now exist linking atypical femoral 
fractures in osteoporotic patients with long-term bisphosphonate treatment, possibly through increases in 
bone mineralization and brittleness due to decreases in bone turnover [42-45]. Our discovery that long-
term bisphosphonate therapy enhances hBMSC-derived osteoblast mineralization, may therefore 
constitute an additional mechanism through which bisphosphonates influence bone mineralization and 
subsequent susceptibility to atypical femoral fractures, independent of their anti-osteoclastic effects.  
Although increases in osteoporotic hBMSC-derived mineral formation induced by high concentrations of 
zoledronate (100 nM) could partly be explained by reductions in cell numbers, this could not account for 
the enhanced levels of mineralization induced by either low zoledronate concentrations (10 nM) or by 
hBMSCs isolated from alendronate-treated osteoporotic patients. The mechanism of action of 
aminobisphosphonates on BMSC-derived mineral formation remains largely undetermined, although 
previous reports have alluded to the fact that aminobisphosphonates may mediate their effects through the 
regulation of various proteins and genes specific to osteogenesis. The activities of alkaline phosphatase 
(ALP) are considered to be an essential prerequisite for the successful initiation of mineralization [46]. As 
such, ALP activity levels are generally used as a measure of osteogenesis in differentiating MSC cultures 
in vitro. Despite the fact that we could demonstrate marked increases in mineral formation in hBMSC 
cultures previously exposed to either zoledronate or alendronate, ALP activity in these cells remained 
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unaffected. These findings are in line with previous studies in which the effects of zoledronate and 
alendronate on hBMSC osteogenesis were evaluated [19, 47]. However, additional reports also exist 
describing the stimulatory effects of both zoledronate and alendronate on ALP activity in differentiating 
hBMSCs [20, 21]. As such, it remains unclear as to the involvement of ALP in regulating the stimulatory 
effects of aminobisphosphonate treatment on hBMSC osteogenesis and subsequent mineral formation. At 
least in the hBMSCs of the osteoporotic individuals used in the current study, ALP activity did not appear 
to represent a critical factor in the mineral-promoting actions of either zoledronate or alendronate. 
At the genetic level, increases in the expression of FGF2, RUNX2, BSP2 and BMP-2 mRNA have been 
observed in hBMSCs treated with alendronate or zoledronate [19, 48]. Similarly, osteocalcin and RUNX2 
protein levels were also found to be elevated in hBMSCs undergoing osteogenic differentiation in 
response to alendronate treatment [20]. In contrast, a more recent study by Ebert et al (2009) [21] 
demonstrated that the stimulatory effects of zoledronate on hBMSC mineralization were associated with a 
downregulation in the expression levels of osteogenic markers OCN, SPP1 and COL1A2. In the present 
report, RUNX2 expression levels were unaltered during osteogenesis and remained at comparable levels 
in all treatment groups. The expression levels of both FGF2 and OCN were significantly downregulated 
upon osteogenic induction in either the presence or absence of aminobisphosphonate. As such, we do not 
consider the stimulatory effects of aminobisphosphonate treatment to be dependent on alterations in these 
osteogenic markers. However, aminobisphosphonate treatment did induce a significant downregulation in 
osteopontin at both mRNA and protein levels in hBMSCs undergoing osteogenic differentiation as 
compared to untreated control cells. Osteopontin is generally considered to be a negative regulator of 
osteogenic differentiation as demonstrated by the fact that cortical bone mineralization is significantly 
enhanced in Spp1
-/-
 mice [49]. Furthermore, deletion of the Spp1 gene from hypomineralized mice 
deficient in the tissue-specific ALP gene, Akp2, partially restored a normal bone phenotype in these mice 
[50]. This, along with its ability to inhibit mineral formation in vitro [51], would suggest that 
downregulation of SPP1 expression in osteoblastic cultures by aminobisphosphonates may represent a 
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plausible means through which they enhance mineral deposition both in vitro and possibly even in vivo. 
This theory is further supported by the results from our loss-of-function studies in which SPP1 gene 
knockdown enhanced mineral formation in osteoporotic hBMSCs undergoing osteogenic differentiation. 
A proposed limitation of this study is that hBMSCs were isolated from female osteoporotic patients only, 
and thus we cannot exclude possible gender-related effects with regards to the differentiation potential of 
the isolated hBMSCs. Despite females representing the majority of osteoporotic (hip) fracture patients, 
further investigations into the osteogenic potential of BMSCs from male osteoporotic patients may 
therefore be warranted. Furthermore, our study is somewhat underpowered due to the limited number of 
aged (> 65 years old) osteoporotic patients that could be recruited for donation of hBMSCs. This was 
especially evident in the case of acquiring samples from osteoporotic patients receiving 
aminobisphosphonate medication. Future studies using larger numbers of patients, in combination with 
more diverse treatment groups, would certainly help clarify the overall impact of bisphosphonate 
treatment on hBMSC osteogenesis and mineralization of differentiating bone-forming cells isolated from 
osteoporotic patients. 
In summary, we demonstrate here that exposure of osteoporotic hBMSCs to aminobisphosphonates 
greatly enhances their capacity for osteoblast-mediated mineral formation, and may thus represent an 
alternative means by which bisphosphonates increase BMD in treated patients. Furthermore, 
downregulation of osteopontin production is implicated as a possible mechanism of action. It is expected 
that further investigations into how bisphosphonates influence hBMSC function will better our 
understanding of how these potent synthetic compounds act to mediate bone quality and turnover in 
osteoporotic patients, and that these insights may ultimately lead to the generation of new and novel 
approaches to treat age-related osteoporotic bone loss. 
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Table 1. Details of patients from which BMSCs were isolated. 
Patient 
(sex) 
Age 
(yrs) 
Mobility 
score
a
 
T-score
b 
 
(femoral 
neck) 
T-score
b
 
(total 
hip) 
T-score
b
 
(lumbar 
spine) 
BMI P1NP
c 
(µg/l) 
β-CTx
c 
(ng/l) 
Anti-osteoporotic 
therapy used 
F 84 2 -2.9 -3.3 -3 18.9 47 932 -  
F 92 4 -2.9 -3.4 -4.6 20.2 61 1194 - 
F 89 9 -2.5 -1.8 -1 23.5 64 864 - 
F 95 6 -2.7 -2.9 -1.9 22.9 37 345 - 
F 84 4 n.d. n.d. -5.1 19.5 47 376 - 
F 90 4 -3.5 -3.6 -5 21.2 108 1033 Ca/Vit.D 
F 85 9 -2.6 -2.4 -2.9 25.0 77 490 -  
F 79 4 n.d. n.d. -4.2 20.8 60 71 
d
Fosamax/Ca/Vit.D 
F 82 9 -3 -2.6 -2.4 23.2 32 284 
d
Fosamax/Ca/Vit.D 
F 85 9 -2.4 -2.4 -3 24.0 24 261 
d
Fosamax/Ca/Vit.D 
a 
Parker mobility score ranging from 0 (no walking ability at all) to 9 (fully independent). 
b
 Determined by DXA analysis where a T-score of -2.5 standard deviations (SD) or less was considered 
osteoporotic. 
c 
Bone turnover markers, P1NP, Serum procollagen type I N propeptide (bone formation marker); β-CTx, 
Serum carboxy-terminal cross-linking telopeptide of type I collagen (bone resorption marker). 
d
 Patients received 70mg of Fosamax (alendronate) once weekly and duration of treatment ranged from 4-
12 years.   
F, female; BMI, body mass index; Ca/Vit.D, calcium/vitamin D; n.d., not determined due to contralateral 
implant following previous hip fracture surgery. 
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Fig. 1 Characterization of hBMSCs isolated from osteoporotic patients. a Expression of surface antigens 
by hBMSCs isolated from aged female osteoporotic patients (n = 3). The expression of surface markers 
associated with mesenchymal cells (CD90, CD105 and CD166) and hematopoietic cells (CD34 and 
CD45) was assessed by fluorescence activated cell sorting (FACS). b Phase contrast image of cultured 
hBMSCs grown under non-differentiating conditions. c Cells differentiated towards adipocytes and 
stained with Oil red O at day 14. d Cells differentiated towards osteoblasts and stained with Alizarin red 
at day 21. Images are representative of at least three separate experiments 
 
Fig. 2 Effect of zoledronate on the mineral formation by differentiating hBMSCs isolated from 
osteoporotic patients. hBMSCs isolated from osteoporotic patients (n = 7) were induced to undergo 
osteogenic differentiation for 14 and 21 days in osteogenic medium (OM) with or without zoledronate (10 
and 100 nM) and mineral formation determined by Alizarin red staining. a Representative images of 
hBMSC cultures isolated from four separate patients stained with Alizarin red at 21 days after osteogenic 
induction. b Quantitative determination of Alizarin red staining normalized to cell number. c Mean cell 
number as determined from at least 9 random fields of view. Data is expressed as mean ± SD. * p<0.05, 
** p<0.01  in comparison to osteogenic medium without ZA (OM) as determined by ANOVA. All 
experiments were performed in triplicate.  
 
Fig. 3 Comparison between osteogenic differentiation of hBMSCs isolated from untreated and 
alendronate-treated osteoporotic patients. hBMSCs isolated from osteoporotic patients receiving 
alendronate treatment (ALN) (n = 3) were induced to undergo osteogenic differentiation for 14 and 21 
days with or without zoledronate (ZA) (10 and 100 nM). Mineral formation was assessed by Alizarin red 
staining and compared to hBMSCs isolated from osteoporotic patients of comparable age and T-score not 
receiving bisphosphonate treatment (Control) (n = 3) cultured at the same time under identical conditions. 
a Representative images of Alizarin red stained hBMSC cultures from each set of patients used. b 
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Quantitative determination of Alizarin red staining normalized to cell number. c Mean cell number as 
determined from at least 9 random fields of view. Data is expressed as mean ± SD. * p<0.05, ** p<0.01  
in comparison to control as determined by ANOVA. All experiments were performed in triplicate. 
 
Fig. 4 Effect of aminobisphosphonate treatment on ALP activity and osteogenic gene expression in 
differentiating hBMSCs. hBMSCs isolated from alendronate treated (ALN; n = 3) or untreated (Control; n 
= 5-6) osteoporotic patients were induced to undergo osteogenic differentiation for up to 21 days with or 
without zoledronate (ZA) (100 nM). a Cell lysates were harvested at 0, 7, 14 and 21 days following 
osteogenic induction and ALP activity determined using an ALP activity assay. Expression levels of 
RUNX2 (b), FGF2 (c), OCN (d), and SPP1 (e) were determined in hBMSCs at days 0, 7 and 14 following 
osteogenic induction using qRT-PCR and values expressed as fold change in mRNA expression relative 
to either control hBMSC at day 0 (Control, Control+ZA) or alendronate-treated hBMSCs at day 0 (ALN, 
ALN+ZA) (value = 1). In all cases, experiments were performed in triplicate and data expressed as mean 
± SD. * p<0.05, ** p<0.01 as determined by ANOVA whereby Control and Control+ZA were compared 
to Control at day 0, and ALN and ALN+ZA were compared to ALN at day 0.  
 
Fig. 5 Effect of osteopontin on the mineralization efficiency of differentiating bone-forming cells isolated 
from osteoporotic patients. a Equal amounts of protein extracts from hBMSCs incubated for 10 days in 
growth medium (lane 1) or in osteogenic medium alone (lane 2) or supplemented with 10 nM (lane 3) or 
100 nM (lane 4) ZA were loaded onto a SDS-PAGE gel and immunoblotting performed using an 
antibody specific for osteopontin. Levels of tubulin were used as a loading control. b qRT-PCR analysis 
of SPP1 gene expression in differentiating osteoporotic hBMSCs at day 7 following transfection with 
either control siRNA (siRNA (C)) or SPP1 siRNA (siRNA (SPP1)). Data was normalized to GUSB and 
expressed as fold change (Log10) as compared to cells transfected with siRNA (C) using the 2
-∆∆CT
 
method. Experiments were performed in triplicate and data expressed as mean ± SD. * p<0.01, in 
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comparison to siRNA (C) as determined by Student’s t-test. c Representative images of Alizarin red 
stained osteoporotic hBMSCs transfected with control siRNA (siRNA (C)) or SPP1 siRNA (siRNA 
(SPP1)) at day 28 post-osteogenic induction.  
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Fig. 1 Characterization of hBMSCs isolated from osteoporotic patients. a Expression of surface antigens 
by  hBMSCs isolated from senile osteoporotic patients (n = 3). The expression of surface markers associated 
with mesenchymal cells (CD90, CD105 and CD166) and hematopoietic cells (CD34 and CD45) was assessed 
by fluorescence activated cell sorting (FACS). b Phase contrast image of cultured hBMSCs grown under non-
differentiating conditions. c Cells differentiated towards adipogenesis and stained with Oil red O at day 14. d 
Cells differentiated towards osteogenesis and stained with Alizarin red at day 21. Images are representative 
of at least three separate experiments  
72x51mm (600 x 600 DPI)  
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Fig. 2 Effect of zoledronate on the mineral formation by differentiating hBMSCs isolated from osteoporotic 
patients. hBMSCs isolated from senile osteoporotic patients (n = 7) were induced to undergo osteogenic 
differentiation for 14 and 21 days in osteogenic medium (OM) with or without zoledronate (10 and 100 nM) 
and mineral formation determined by Alizarin red staining. a Representative images of hBMSC cultures 
isolated from four separate patients stained with Alizarin red at 21 days after osteogenic induction. b 
Quantitative determination of Alizarin red staining normalized to cell number. c Mean cell number as 
determined from at least 9 random fields of view. Data is expressed as mean ± SD. * p<0.05, ** p<0.01 in 
comparison to osteogenic medium without ZA (OM) as determined by ANOVA. All experiments were 
performed in triplicate.  
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Fig. 3 Comparison between osteogenic differentiation of hBMSCs isolated from untreated and alendronate-
treated osteoporotic patients. hBMSCs isolated from senile osteoporotic patients receiving alendronate 
treatment (ALN) (n = 3) were induced to undergo osteogenic differentiation for 14 and 21 days with or 
without zoledronate (ZA) (10 and 100 nM). Mineral formation was assessed by Alizarin red staining and 
compared to hBMSCs isolated from osteoporotic patients of comparable age and T-score not receiving 
bisphosphonate treatment (Control) (n = 3) cultured at the same time under identical conditions. a 
Representative images of Alizarin red stained hBMSC cultures from each set of patients used. b Quantitative 
determination of Alizarin red staining normalized to cell number. c Mean cell number as determined from at 
least 9 random fields of view. Data is expressed as mean ± SD. * p<0.05, ** p<0.01 in comparison to 
control as determined by ANOVA. All experiments were performed in triplicate.  
96x92mm (300 x 300 DPI)  
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Fig. 4 Effect of aminobisphosphonate treatment on ALP activity and osteogenic gene expression in 
differentiating hBMSCs. hBMSCs isolated from alendronate treated (ALN; n = 3) or untreated (Control; n = 
5-6) senile osteoporotic patients were induced to undergo osteogenic differentiation for up to 21 days with 
or without zoledronate (ZA) (100 nM). a Cell lysates were harvested at 0, 7, 14 and 21 days following 
osteogenic induction and ALP activity determined using an ALP activity assay. Expression levels of RUNX2 
(b), FGF2 (c), OCN (d) and SPP1 (e) were determined in hBMSCs at days 0, 7 and 14 following osteogenic 
induction using qRT-PCR and values expressed as fold change in mRNA expression relative to either control 
hBMSCs at day 0 (Control, Control+ZA) or alendronate-treated hBMSCs at day 0 (ALN, ALN+ZA) (value = 
1). In all cases, experiments were performed in triplicate and data expressed as mean ± SD. * p<0.05, ** 
p<0.01 as determined by ANOVA whereby Control and Control+ZA were compared to Control at day 0, and 
ALN and ALN+ZA were compared to ALN at day 0.  
561x401mm (72 x 72 DPI)  
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Fig. 5 Effect of osteopontin on the mineralization efficiency of differentiating bone-forming cells isolated 
from osteoporotic patients. a  Equal amounts of protein extracts from hBMSCs incubated for 10 days in 
growth medium (lane 1) or in osteogenic medium alone  (lane 2) or supplemented with 10 nM  (lane 3) or 
100 nM  (lane 4) ZA were loaded onto a SDS-PAGE gel and immunoblotting performed using an antibody 
specific for osteopontin. Levels of tubulin were used as a loading control. (b)  qRT-PCR analysis of SPP1 
gene expression in differentiating osteoporotic hBMSCs at day 7 following transfection with either control 
siRNA (siRNA (C)) or SPP1 siRNA (siRNA (SPP1)). Data was normalized to GUSB and expressed as fold 
change (Log10) as compared to cells transfected with siRNA (C) using the 2-∆∆CT method. Experiments were 
performed in triplicate and data expressed as mean ± SD. * p<0.01, in comparison to siRNA (C) as 
determined by Student’s t-test. (c) Representative images of Alizarin red stained osteoporotic hBMSCs 
transfected with control siRNA (siRNA (C)) or SPP1 siRNA (siRNA (SPP1)) at day 28 post-osteogenic 
induction.  
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